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Life-threatening fungal infections have increased in recent years while treatment options remain limited. The
development of vaccines against fungal pathogens represents a key advance sorely needed to combat the
increasing fungal disease threat. Dendritic cells (DC) are uniquely able to shape antifungal immunity by initi-
ating and modulating naive T cell responses. Targeting DC may allow for the generation of potent vaccines
against fungal pathogens. In the context of antifungal vaccine design, we describe the characteristics of the
varied DC subsets, howDC recognize fungi, their function in immunity against fungal pathogens, and howDC
can be targeted in order to create new antifungal vaccines. Ongoing studies continue to highlight the critical
role of DC in antifungal immunity and will help guide DC-based vaccine strategies.Introduction
Fungal pathogens are a serious emerging infectious disease
threat and are the target of efforts to develop novel vaccines.
The rising danger of mycoses is compounded by both the
paucity and toxicity of the pharmacological armamentarium
available to treat these infections and the immunocompromised
status of the large majority of patients with fungal infections.
While fungi are commonly encountered by humans in their
environment, particularly as inhaled spores or conidia, few fungal
species are human pathogens. Fungi also exist as useful
commensal organisms until the host becomes immunodeficient
or a systemic portal like a venous catheter is colonized, where-
upon commensal fungi can cause life-threatening infections.
Thus, the development of fungal vaccines faces the dual chal-
lenge of providing protection to immunocompromised patients
and protection against primary pathogens that cause lethal
infections in healthy individuals.
The rising incidence of fungal infections is linked to the
increase in immunocompromised individuals, specifically,
patients with AIDS, patients with cancer, and recipients of solid
organ or hematopoietic stem cell transplants. Candida species
are the second leading cause of infectious disease-related death
in premature infants and the fourth leading cause of hospital
bloodstream infections (Benjamin et al., 2010; Pfaller and
Diekema, 2007). A rise in the incidence of zygomycosis is also
noted in patients with diabetes mellitus (Bitar et al., 2009), aug-
menting clinical challenges in this growing patient population.
Major endemic mycoses can lead to lethal systemic infections
in apparently healthy individuals and can reactivate in the setting
of immune suppression. Also, fungal-associated allergy and
asthma contribute significantly to the human health burden
due to fungi.
Encounters with fungi require a coordinated host innate and
adaptive immune response to successfully eradicate the fungus
and to promote long-lived immunological memory of the436 Cell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc.encounter. Iatrogenic risk factors for fungal infections such as
granulocytopenia, compromised mucosal barriers, and T cell-
suppressing drugs demonstrate important roles for both innate
and adaptive responses to fungi. In fungal infections, both
CD4+ and CD8+ T cells participate in the elimination of the path-
ogen (Cutler et al., 2007). Most fungi also elicit antibodies, some
of which are protective and can neutralize fungal pathogens or
promote fungal uptake by phagocytes (see accompanying
review by Casadevall and Pirofski [2012]). Phagocytes and other
innate immune cells play a critical role in combating fungal path-
ogens (reviewed by Brown, 2011). Activated phagocytes and
neutrophils kill fungi either following phagocytosis or via the
production of fungicidal chemicals, including reactive oxygen
and nitrogen species. Epithelial cells also produce fungicidal
compounds such as b-defensin and provide a mechanical
barrier at mucosal sites exposed to fungi. Expectedly, genetic
or acquired deficiency in either the innate or adaptive immune
response significantly increases the risk of fungal infection.
For example, individuals with an early stop codon mutation in
Dectin-1 suffer recurrent mucocutaneous fungal infections
(Ferwerda et al., 2009) whereas Pneumocystis pneumonia is
a frequent AIDS-defining diagnosis (Huang et al., 2011).
At the intersection of innate and adaptive immunity are
dendritic cells (DC), unique cells capable of taking up and
processing antigen for presentation by major histocompatibility
complex (MHC) class I or MHCII molecules to naive T cells and
also themselves possessing potent fungicidal activity. DC recog-
nize fungi via a broad array of surface and intracellular pattern
recognition receptors (PRR). Recognition of fungi results in the
secretion of cytokines by DC and the expression of costimula-
tory molecules on the DC surface, both of which are required
to drive naive CD4+ T cell differentiation into a T helper (Th)
phenotype. Clearance of fungi with limited damage to the host
requires a finely tuned balance between Th1, Th17, and Treg
subsets; the precise response needed is based on the
Figure 1. Location of DC Subsets Important in Antifungal Immunity
DC subsets and monocytes arise from a common precursor in the bone marrow. pDC, monocytes, and PreDC exit the bone marrow and circulate via the blood.
Resident CD8+ and CD8- DC exist in the spleen and the lymph node. PreDC seed the lungs, skin, and intestine and give rise to DC subsets in those locations.
Migratory DC subsets migrate from peripheral locations to draining lymph nodes where they interact and prime T cells. In the lungs, CD103+ DC sample antigen
from the airway lumen via paracellular processes. CD11b+ DC and CD103+ DC migrate to mediastinal lymph nodes. The epidermis of the skin contains a unique
DC subset, Langerhans cells (LC), that are seeded in utero and self-renew. LC sample antigen and migrate via the dermis to skin-draining lymph nodes. Dermal
DC also migrate to skin-draining lymph nodes. In the intestine, DC exist in the Peyer’s Patch (PP) and the lamina propria (LP). PP-DC sample antigen-using
transcellular processes from the intestinal lumen, following which they migrate to the T cell-rich area of the PP, where PP-DC prime T cells. LP-DC subsets
migrate to the mesenteric lymph node following antigen sampling. During inflammation, monocytes enter inflamed tissue and differentiate into monocyte-derived
DC (Mo-DC), which then carry antigen to draining lymph nodes.
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brate and orchestrate the balance of helper, regulatory, and
effector T cell responses, thus integrating innate and adaptive
immune responses to fungi.
The unique ability of DC to initiate and engage antifungal
immunity positions them as logical cellular targets for the devel-
opment of fungal vaccines. In this review, we describe the
panoply of DC subsets and their function in antifungal immunity,
identify how DC recognize fungi, and discuss strategies to target
DC in the development of novel antifungal vaccines. We empha-
size DC subsets using murine surface markers; corresponding
human DC subset markers continue to be elucidated and are
reviewed elsewhere (Naik, 2008).
Characterization and Function of DC and Monocyte
Subsets
Four decades ago, Steinman and Cohn reported the identifica-
tion of a cell with ‘‘continually elongating, retracting, and reor-
ienting’’ long cytoplasmic processes in the spleen and lymphnodes of mice (Steinman and Cohn, 1973). These cells, now
known as DC, are hematopoietic cells that function as profes-
sional antigen-presenting cells and that are capable of initiating
a T cell response. When DC encounter antigen at the boundary
of immunological defense sites such as the skin or the airways
of the lung or in the draining nodes of the lymphatic system, DC
amplify the innate immune response by secreting cytokines
that recruit and activate other leukocytes. Following engulf-
ment, processing, and presentation of the antigen, DC initiate
and shape adaptive responses by promoting naive T cell differ-
entiation into effector or regulatory T cells. Since their
discovery, a plethora of DC subsets characterized by anatom-
ical location, function, and surface marker expression have
been described (Figure 1). Indeed, it is the specialized functions
of the diverse DC subsets that augment the challenge of
targeting DC in the development of antifungal vaccines. There-
fore, ongoing efforts to characterize the function of DC subsets
will enhance the rational design of DC-targeted antifungal
vaccines.Cell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc. 437
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progenitor cell in the bone marrow, the macrophage-dendritic
cell progenitor (MDP) (Fogg et al., 2006; Liu et al., 2009). From
the MDP, a common-DC progenitor and monocytes are pro-
duced. The common-DC progenitor (CDC), which is restricted
to the bone marrow gives rise to three broad groupings of DC:
plasmacytoid DC (pDC), conventional DC, and migratory DC.
While monocytes and pDC mature in the bone marrow and are
released into the blood for circulation to lymphoid tissues, resi-
dent and migratory DC precursors, known as preDC, exit the
bone marrow and circulate via the blood before either entering
the high endothelial venules of lymphoid tissues or seeding
peripheral tissues.
Plasmacytoid DC
pDC are typified by their high production of interferon-a (IFN-a) in
response to the sensing of nucleic acids by endosomal Toll-like
receptors and are further characterized in part by the high
surface expression of sialic acid binding immunoglobulin-like
lectin H (Siglec H). Using a Siglec H-DTR depleter mouse,
a recent study further elucidated the roles of pDC in vivo (Takagi
et al., 2011). Besides nucleic acid sensing, pDC induced IL-10
producing CD4+ Foxp3+ Treg cells, limited Th1 and Th17 cell
polarization at mucosal sites, and activated CD8+ T cells.
Furthermore, pDC controlled viral infection via the induction of
CD8+ T cells, but impaired bacterial clearance and contributed
to septic shock. While pDC carry out a well-characterized role
in antiviral immunity, the role of pDC in fungal infections is less
clear. pDC recognize Aspergillus fumigatus DNA via TLR9 and
are linked with resistance to A. fumigatus infection in mice
(Ramirez-Ortiz et al., 2011). Moreover, pDC inhibited fungal
growth in vitro and accumulated in the lungs in a murine model
of Aspergillus pulmonary infection, suggesting that pDC may
recognize and combat fungi directly in vivo. A second subset
of pDC exists that develops in the context of elevated IFN-a
and is similar to pDC found in Peyer’s patches of the gut
(Li et al., 2011). Uncharacteristically, this pDC subset fails to
produce IFN-a after stimulation with TLR ligands; however, this
pDC subset secreted elevated levels of IL-6 and IL-23 and
primed robust antigen-specific Th17 cells in vivo. This suggests
a potential role for IFN-a-elicited pDC in the polarization of anti-
fungal Th17 cells. Combined with the recent findings that pDC
are critical mediators of Treg/Th17 balance at mucosal surfaces,
recognition of fungi by pDC or IFN-a elicited pDC at mucosal
surfaces may tilt the balance toward tolerance or inflammation.
Conventional DC
Conventional DC, also known as resident DC, exist in the
lymphoid tissue and are comprised of twomajor subpopulations,
CD8+ and CD4+CD8- resident DC. In addition, the spleen
contains a third minor population of so-called double-negative
DC, which lack CD4 and CD8 surface expression and appear
to be largely similar in function to CD4+CD8- DC (Luber et al.,
2010). CD8+ resident DC are identified by the surface phenotype
CD8+CD4-CD11b-CD11c+MHCII+DEC205+ and are located
primarily in the T cell zone of the spleen and lymph nodes
(Idoyaga et al., 2009). A major function of CD8+ DC is the
cross-presentation of antigens via MHCI to CD8+ cytotoxic
T lymphocytes (CTL) (den Haan et al., 2000). CD8+ DC obtain
antigen via the engulfment of live or apoptotic cells or antigen-
containing apoptotic vesicles. CD4+CD8- resident DC are438 Cell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc.identified by the surface phenotype CD8-CD4+CD11b+CD11c+
MHCII+33D1+ and are present in the red pulp and bridging chan-
nels of the spleen and the marginal zones and high endothelial
venules of the lymph nodes (Liu and Nussenzweig, 2010). In
contrast to CD8+ DC, CD4+CD8- DC are not efficient at present-
ing antigens via MHCI and instead present antigen via MHCII
(Dudziak et al., 2007).
Relative to other pathogen classes such as viruses, informa-
tion regarding the role of resident DC in priming T cell responses
to fungi is limited. Direct evidence that resident DC prime
antifungal T cell responses was demonstrated in a vaccine
model to generate immunity to Blastomyces dermatitidis. Lymph
node resident DC acquired and displayed antigen and primed
antigen-specific CD4+ T cells, however acquisition of the antigen
depended on ferrying of the yeast from the skin to the lymph
node by migratory and monocyte-derived DC (Ersland et al.,
2010). Less is known about cross-presentation of fungal
antigens in vivo. Bone marrow-derived DC acquire and cross-
present Histoplasma capsulatum antigens to CTL via ingestion
of live or killed Histoplasma capsulatum yeasts or via engulfment
of Histoplasma containing apoptotic macrophages (Lin et al.,
2005). Subcutaneous injection of apoptotic phagocytes contain-
ing CFSE-labeled heat-killedHistoplasma results in the accumu-
lation of CFSE in CD11c+ cells in skin-draining lymph nodes
and CD11c+-dependent CTL-mediated protection against
Histoplasma challenge (Hsieh et al., 2011). While these studies
provide evidence that fungal antigens can be acquired and
presented by resident DC, the precise resident DC subpopula-
tion or subpopulations involved in vivo remain undefined.
Unexpectedly, CD4+CD8- resident DC may be important for
the cross-presentation of fungal antigens. In experiments using
an OVA-expressing strain of the model yeast Saccharomyces
cerevisiae, both CD8+ and CD4+CD8- DC isolated from mouse
spleen and primed with OVA-S. cerevisiae induced robust
OVA-specific CD4+ T cell proliferation ex vivo, however only
CD4+CD8- DC stimulated an OVA-specific CD8+ T cell response
(Backer et al., 2008). To that end, further studies will be needed
to unravel the specific contributions of resident DC subpopula-
tions to CD4+ T cell and CTL activation and polarization in vivo.
Migratory DC
Migratory DC, also referred to as tissue DC, are immature DC
that are located principally in peripheral tissues such as the
skin, the lung, and the gut. Following uptake of antigen, migra-
tory DC exit the tissue and undergo maturation characterized
by (1) enhanced antigen processing and presentation, (2) down-
regulation of tissue homing receptors, (3) upregulation of CCR7,
and (4) increased surface expression of costimulatory mole-
cules. CCR7+ DC migrate to the T cell zone of lymphoid tissue,
where they can initiate activation of naive T cells or transfer
antigen to resident DC (Banchereau and Steinman, 1998; Allan
et al., 2006). With the exception of Langerhans cells in the
epidermis, the majority of migratory DC appear to derive from
the same circulating precursor as conventional DC, the preDC.
Migratory DC have some capacity for division and self-renewal
in situ, while monocyte subsets also contribute to replenishment
of migratory DC in certain circumstances. Migratory DC line the
surfaces of the body that are exposed to the environment and, as
such, are likely to encounter fungi along with other pathogens
and antigens. While the migratory DC networks that line the
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tional differences that are important in antifungal immunity and
deserve individual discussion.
Skin
The skin is lined by a dense network of DC which can be broadly
divided into the epidermis-associated Langerhans cell (LC) and
a collection of dermis-associated dermal DC (Henri et al.,
2010a). LC are unique among migratory DC as they arise from
a MDP-like cell seeded into the epidermis in utero followed by
a wave of expansion within days of birth (Chorro et al., 2009).
In addition to their epidermal location, LC are characterized by
surface expression of the eponymous langerin (CD207),
CD11c, and MHCII. The dermis contains LC that migrate to the
draining lymph node, CD207+CD103+ dermal DC, and a diverse
group of CD207-CD103- DC (Henri et al., 2010b). Upon subcuta-
neous administration of a B. dermatitidis vaccine, DEC205
expressing skin-derived DC migrated to the skin-draining lymph
node in a CCR7-dependent fashion, presented the model
antigen expressed by the fungus, and activated CD4+ T cells
(Ersland et al., 2010).
Specialized antigen presentation and T cell polarization func-
tions for skin-associated DC subsets—specifically LC, CD207+
dermal DC, and CD207- dermal DC—were elegantly assessed
in a cutaneous epidermal exposure model to Candida albicans
(Igya´rto´ et al., 2011). LC were necessary and sufficient for the
generation of antigen-specific Th17 cells via the production of
elevated levels of IL-6, IL-1b, and IL-23, cytokines which
promote and stabilize Th17 development. In contrast, LC were
not necessary for the generation of CTL. CD207+ dermal DC
were required for CTL and also Th1 polarization. Compared
with LC, CD207+ dermal DC produced higher levels of IL-12
and IL-27 and lower levels of IL-1b and IL-6 and no IL-23, making
them poor promoters of Th17. Moreover, the CD207
+ dermal DC
inhibited the ability of LC and CD207- dermal DC to promote
Th17 responses. Since IL-12 and IL-27, as well as IFN-g from
Th1 cells, inhibit Th17 differentiation and proliferation, CD207
+
dermal DC likely block Candida-specific Th17 cells by promoting
Th1 differentiation. Thus, exposure of LC and CD207
+ dermal DC
to Candida can promote opposing effects, through the elabora-
tion of polarizing cytokines that enable the development of Th1 or
Th17 responses. Importantly, this study identified a subset of DC
that, when targeted, skews differentiation toward Th17 cells,
which are instrumental in antifungal immunity (Igya´rto´ et al.,
2011; also see the accompanying review by Herna´ndez-Santos
and Gaffen [2012]).
Lung
DC in the lung and conducting airways deal with constant expo-
sure to inhaled fungal spores and hyphal fragments. A dense
network of DC line the airways, sampling inhaled antigen for
subsequent shuttling to mediastinal lymph nodes. Indeed, the
airway is currently a target for intranasally delivered vaccine
against influenza and may represent a candidate vaccine site
against inhaled fungi. Besides pDC, lung DC subsets include
two broad divisions: CD103+ DC and CD11b+ DC. CD103+
lung DC also express CD207, making them similar to
CD207+CD103+ dermal DC in the skin. CD103+ DC express tight
junction proteins, which allow the DC to intimately associate with
airway epithelial cells and to extend dendrites into the airway
lumen to sample antigen without disturbing the epithelial barrier(Sung et al., 2006; Jahnsen et al., 2006). Steady state migration
of CD103+ DC and CD11b+ DC in the absence of inflammation is
responsible for the induction of tolerance to inhaled antigen.
CD103+ DC can acquire both soluble and apoptotic cell-associ-
ated antigens from the airway following which CD103+ DC
migrate to the mediastinal lymph node under both steady state
and inflammatory conditions. In the mediastinal lymph node
CD103+ DC cross-present antigen to and activate CTL (Desch
et al., 2011). CD11b+ DC differ from monocyte-derived DC and
specialize in cytokine and chemokine production (Beaty et al.,
2007), as well as presenting antigen via MHCII to CD4+ T cells
in the mediastinal lymph node following migration (del Rio
et al., 2007). Rapid recruitment of Ly6C+ monocyte-derived DC
to the lung upon inflammation clouds analysis of the function
of lung CD11b+ DC, which lack Ly6C surface expression.
Upon pulmonary exposure to A. fumigatus conidia, CD103+ DC
failed to take up and transport conidia to the mediastinal lymph
node, whereas CD11b+ DC did transport them (Hohl et al., 2009).
In this model, lung CD11b+ DC were reduced relative to wild-
type mice in CCR2/ mice following A. fumigatus exposure.
Conversely, naive CCR2/ mice had similar lung CD11b+ DC
numbers to wild-type mice, suggesting that recruited mono-
cyte-derived DC (discussed in detail later in this review) and
not lung CD11b+ DC are responsible for conidial uptake and
antigen presentation in the setting of A. fumigates-induced
inflammation.
Intestine
Just like the lung, DC in the intestine are situated on the basolat-
eral side of the epithelial layer largely isolated from the gut
microflora. DC in the intestine localize to two major subepithelial
locations, the lamina propria and the Peyer’s patch; both
subsets in each region differentially regulate immune responses.
The Peyer’s patch is a specialized structure that consists of
organized T and B cell follicles capped by a unique epithelial
cell dome called an M cell. Peyer’s patch DC (PP-DC) extend
dendrites through M cells to sample antigen from the intestinal
lumen. This transcellular method of antigen sampling appears
to be distinct from the paracellular sampling that occurs in the
lung and outside of the PP in the intestine (Lelouard et al.,
2012). Following antigen internalization, PP-DC migrate to the
T cell-rich zone of the PP to prime naive T cells.
Lamina propria DC (LP-DC) express CD11c, MHCII, and
CD103 and can be further divided into CD11b+ and CD11b-
subsets. CD11b+ and CD11b- LP-DC subsets represent two
sides of an equilibrium that maintain the balance between the
induction of Th17 and Treg responses, respectively, in the intes-
tinal wall (Denning et al., 2011). Indeed, CD11b+ LP-DC numbers
are elevated in the duodenum and gradually decrease
throughout the small intestine and reach their lowest levels in
the colon, mirroring the distribution of Th17 cells. LP-DC play
distinct roles in directing CD4+ T cell differentiation in the lamina
propria dependent on the local LP-DC to T cell ratio and DC-T
cell location along the intestine. Furthermore, the gut microbiota
plays a key role in shaping the function of these subsets, as
LP-DC from mice obtained from separate vendors display strik-
ingly different efficiencies at priming Th17 cells based in part on
the presence or absence of segmented filamentous bacteria
(Sczesnak et al., 2011). In addition to their ability to affect
T cell responses locally in the intestine, both subsets of LP-DCCell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc. 439
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further prime and activate T cells.
The role of PP-DC and LP-DC in generating antifungal immu-
nity in the gut is unclear and relatively unstudied. C. albicans,
a gut commensal fungus, can cause systemic infection if the
gut epithelial/DC barrier is substantially breached and/or in the
setting of broad-spectrum antibiotic use leading to Candida
overgrowth. Strong induction of Treg cells by LP-DC in the
mesenteric lymph node may highlight the critical role of limiting
inflammation in the gut in order to maintain the epithelial barrier
and prevent disseminated infection. Furthermore, heightened
Th17 responses in the gut impair protective Th1 responses and
worsen Candida infection (Zelante et al., 2007). While bone
marrow-derived DC produced IL-23 in response to Candida
in vitro and IL-23 neutralization promoted fungal clearance
in vivo, the identity of the DC subset recognizing and responding
to the fungus in this model was not determined. Nevertheless,
DC in the gut appear to tightly control tolerance and immunity
to fungal organisms.
Monocytes,Monocyte-DerivedDC,and InflammatoryDC
Monocytes are derived from the MDP and, in the absence of
inflammation, are found in the bone marrow and circulating
at low levels in the blood and spleen. Two classes of
CD11b+CD115+ monocytes arise from the MDP and circulate
in the blood, Ly6C+CCR2+ and Ly6C-CX3CR1hi monocytes
(Geissmann et al., 2003). Monocytes have broad developmental
plasticity and can replenish certain subsets of DC and LC in
the setting of experimental depletion (Ginhoux et al., 2007) and
thus may represent an emergency store of DC precursors that
can be rapidly deployed. Under inflammatory conditions
Ly6C+CCR2+ monocytes migrate to the site of inflammation
and acquire surface expression of the DC markers CD11c and
MHCII while losing Ly6C (Osterholzer et al., 2009), thus
becoming ‘‘inflammatory DC.’’ While Ly6C-CX3CR1hi mono-
cytes appear not to be directly involved in innate immunity to
fungi (Domı´nguez and Ardavı´n, 2010), Ly6C+CCR2+ monocytes
play a critical role in responding tomanymedically relevant fungi,
such as A. fumigatus (Hohl et al., 2009), Cryptococcus neofor-
mans (Osterholzer et al., 2009), and B. dermatitidis (Ersland
et al., 2010).
Compared with any other DC subset, monocyte-derived DCs
seem to have an outsized role in antifungal immunity, particularly
through the induction of Th1 cells. Using CCR2
/ mice (where
monocytes are trapped in the bone marrow), inflammatory DC
were found to have a critical role in driving a Th1 response and
presenting Histoplasma antigen to CD4+ T cells (Szymczak and
Deepe, 2010). CCR2/mice also exhibit skewed Th2 responses
in H. capsulatum infection and dramatically greater fungal
burden in the lung compared to wild-type (WT) animals (Szymc-
zak and Deepe, 2009). Similar CCR2-dependent phenotypes are
found in experimental pulmonary infection with A. fumigatus or
C. neoformans: priming of Th1 cells in response to fungi critically
depends on CCR2+ monocyte-derived inflammatory DC (Oster-
holzer et al., 2009; Hohl et al., 2009). To highlight the importance
of the tissue environment in DC function, the defect in CD4+ T cell
priming by inflammatory DC during respiratory infection with
A. fumigatus is restricted to the lung in CCR2/ mice and not
other lymphoid organs such as the spleen (Hohl et al., 2009).
Similarly, while Ly6C+CCR2+ monocytes play a prominent role440 Cell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc.in delivering B. dermatitidis yeast into skin-draining lymph nodes
after subcutaneous vaccine delivery, this shuttling function can
be compensated in CCR2/ mice by other skin migratory DC
populations (Ersland et al., 2010). Thus, in the setting of the
lung, which is the primary route of infection for fungi, but not
the skin or the spleen, monocyte-derived DC appear to play
a critical role in antifungal immunity (Wu¨thrich et. al., 2012).
Fungal Recognition by DC
Recognition of fungi by DC is accomplished by a diverse group
of PRR that recognize conserved fungal PAMP, including
proteins, carbohydrates, and nucleic acids (Figure 2). Antifungal
immunity depends critically on the recognition of fungi by PRR.
Fungal recognition by PRR induces intracellular signaling path-
ways that lead to DC maturation and secretion of cytokines
that instruct the evolving immune response. PRR can also
mediate the uptake of fungi by DC and can direct fungi to
appropriate intracellular compartments for antigen processing
and subsequent presentation. PRR important for the recognition
of fungi include Toll-like receptors (TLR) and C-type lectin
receptors (CLR), which can respond individually or synergisti-
cally to fungi. Other fungal PRR include scavenger receptors,
such as SCARF1 and CD36, that can mediate binding to
C. neoformans (Means et al., 2009) and complement/Fc recep-
tors, which recognize complement factor or antibody-coated
fungi directly (Taborda and Casadevall, 2002) and mediate
phagocytosis.
TLR
Recognition of PAMP by TLR results in engagement of intracel-
lular signaling pathways culminating in the activation of the tran-
scription factors activator protein-1 (AP-1) and nuclear factor-kB
(NF-kB). All TLR transmit their PAMP recognition event via
TIR-mediated engagement of myeloid differentiation primary
response gene 88 (MyD88) with the exception of TLR3, which
recruits the adaptor TIR-domain containing adaptor-inducing
IFN-beta (TRIF). A subset of TLR are also able to activate inter-
feron regulatory factor 3 (IRF3) or IRF7 which regulate the
expression of type I IFN. Since MyD88 is instrumental in priming
Th1 cells in response to fungi (Rivera et al., 2006), it is generally
thought that fungal recognition by TLR induce a Th1 response.
The role of TLR for the induction of antifungal Th17 cells is less
clear. By using naive fungus-specific T cell receptor transgenic
cells, a recent study demonstrated that TLR-induced MyD88
activity, and not dectin-1 or IL-1R signaling, was required for
the development of vaccine-induced Th17 cells and resistance
to B. dermatitidis infection (Wu¨thrich et al., 2011). The identity
of the TLR driving this response is unknown. TLR are globally ex-
pressed on DC, although some subsets of DC may express only
a subset of TLR. For example, TLR3 is expressed 28-fold more
by CD8+ DC than by CD4+CD8- DC in the spleen (Edwards
et al., 2003), suggesting that DC subsets are differentially acti-
vated by discrete fungal TLR ligands.
TLR2
While TLR-mediated signaling in DC generally favors the devel-
opment of Th1 responses, TLR2 signaling may promote nonpro-
tective Th2 or Treg differentiation. TLR2-mediated recognition of
C. albicans results in increased IL-10 production and a concur-
rent decrease in Th1 polarization (Netea et al., 2004). As a result,
TLR2/ mice showed increased resistance to disseminated
Figure 2. Recognition of Fungi via DC PRR
TLR and CLR. Fungal PAMP are recognized by several PRR: Dectin-1 signals via the tyrosine kinase Syk following recognition of bglucan. Dectin-2 and Mincle,
which also signal via Syk following recruitment of Fcg, recognize alpha-mannan and alphamannose respectively. Signaling downstream of themannose receptor
(MR) is undefined. TLR and CLR signaling results in downstream activation of the transcription factors NF-kB or AP-1. Some TLR signaling activates IRF3. While
fungi activate the NLRP3 inflammasome, the mechanism is undefined. TLR recognize fungal carbohydrates, fungal DNA, and fungal RNA at the DC surface or in
endosomal compartments.
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and decreased IL-10 production. Further evidence for the anti-
inflammatory role of TLR2 signaling in DC was provided by two
additional studies. First, DC recognition of zymosan via TLR2
and dectin-1 promoted Treg cell differentiation via IL-10 and
TGF-b secretion (Dillon et al., 2006). Second, live A. fumigatus
hyphae reduced IL-12 and IL-23 production and increased IL-
10 production from DC exposed to house dust mite extract in
a TLR2 and dectin-1 dependent fashion, suggesting that TLR2
recognition of fungal ligands may promote tolerance rather
than protective immunity.
TLR4
Recognition of fungal ligands by TLR4 similarly engenders
heterogeneous responses that fail to recapitulate TLR4-medi-
ated responses to the prototypical TLR4 ligand LPS. For
example, recognition of C. albicans-derived O-linked mannosyl
residues by TLR4 promotes proinflammatory cytokines. By
contrast, TLR4 binding of theC. neoformans cell wall component
glucuronoxylomannan (GXM) does not induce cytokine produc-
tion despite inducing NF-kB nuclear translocation. As TLR4
signaling in response to LPS requires the assembly of a larger
complex consisting of CD14 and MD-2, it is likely that fungal
recognition by TLR4 will require accessory signaling molecules
that may mediate disparate TLR4-mediated responses to
different fungal PAMP.TLR3, TLR7, and TLR9
Multiple studies have demonstrated that fungi are recognized by
the endosomal nucleic acid sensing TLR: TLR3, TLR7, and TLR9.
For instance, cryptococcal DNA triggered IL-12p40 and CD40
expression in murine DCs and activated NF-kB in TLR9-trans-
fected HEK239 cells (Nakamura et al., 2008). Similarly,
A. fumigatus DNA stimulated the production of proinflammatory
cytokines in mouse and human DC (Ramirez-Ortiz et al., 2008).
Drug-resistant Candida glabrata represents an important
emerging opportunistic infection. A recent study demonstrated
that C. glabrata induces Type I IFN secretion from DC in
a TLR7-dependent, but TLR2- and TLR4- independent, manner
(Bourgeois et al., 2011). TLR9 is often targeted with synthetic
oligonucleotides that act as strong adjuvants in new vaccine
designs. As more is learned about fungal recognition by these
TLR and the responses they engender by DC, fungal ligands
may provide additional tools to promote antifungal vaccine
immunity.
CLR
Like the TLR, CLR recognize a broad range of PAMP present on
fungi. CLR recognize glucan-, mannose-, or fucose-containing
structures on fungi and trigger intracellular signaling via ITAM-
containing adaptor molecules leading to maturation of DC and
the secretion of cytokines. DC express a wide range of CLR,
although expression of some CLR are restricted to a particularCell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc. 441
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Reviewsubset of DC contributing to the functional differences of the DC
subsets.
Dectin-1
Prior to the discovery of dectin-1 as the receptor for b-glucan,
fungal b-glucans were already in use as powerful immunomodu-
lators and vaccine adjuvants. The discovery of dectin-1 (Brown
and Gordon, 2001) has allowed for greater elucidation of the
mechanism by which b-glucans exert their effects. Dectin-1
signals via an intracellular domain containing a hemITAM motif
that can recruit and activate the tyrosine kinase Syk. Recruitment
of Syk by activated dectin-1 results in activation of MAPK, NFAT,
and NF-kB via the CARD9 adaptor. Activation of dectin-1 by cur-
dlan, a highly purified b-glucan, elicited IL-6, IL-23, and IL-12
from DC. Curdlan-exposed DC loaded with antigen could drive
differentiation of naive CD4+ T cells into Th17 and Th1 cells, prime
protective CTL cells, and promote antibody responses suggest-
ing that dectin-1 links DC recognition of b-glucans to both T cell
and B cell adaptive immunity (Leibundgut-Landmann et al.,
2008). While dectin-1 is critical for driving antifungal Th17 cells
and resistance to C. albicans, A. fumigatus, and Pneumocystis
carinii, it was found that vaccine-induced Th17 cells and immu-
nity to B. dermatitidis are dectin-1 independent (Wu¨thrich
et al., 2011). Dectin-1 can also mediate uptake of fungi by DC
via recognition of surface b-glucan. Many fungi, including
H. capsulatum, mask b-glucan on their surfaces (Rappleye
et al. 2007), highlighting the powerful role of dectin-1 in the
recognition and response to fungi.
Dectin-2 and Mincle
While dectin-1 recognizes b-glucan, dectin-2 and Mincle recog-
nize mannose-like structures and require the adaptor FcRg
to signal via Syk. Dectin-2 is most abundantly expressed on
inflammatory monocytes and DC. Recognition of a-mannans
by dectin-2 induces the secretion of IL-2, IL-10, and TNF-a by
DC in vitro (Robinson et al., 2009). Furthermore, in a model of
systemic C. albicans infection, dectin-2/ mice or mice treated
with a dectin-2 neutralizing mAb failed to develop Candida-
specific Th17 cells. Mincle also induces the production of
TNF-a, CXCL1, CXCL2, and IL-10 via Syk and CARD9 upon
recognition of C. albicans, Malassezia species, and Fonsecaea
pedrosoi, yet whether Mincle engagement on DC by fungal
PAMP promotes antifungal immunity remains to be investigated
(Sousa et al., 2011). Mincle, which also recognizes amycobacte-
rial glycolipid, is already the target of novel vaccine designs
against mycobacterial pathogens and may prove to be a fruitful
target in antifungal vaccination efforts.
The Mannose Receptor
The mannose receptor (CD206) is a transmembrane protein that
binds terminal mannose, N-acetyl glucosamine, or fucose
sugars and that lacks classical signaling motifs. It can also be
cleaved from the cell surface and exists as a soluble receptor
in some circumstances. In response to fungal N-linkedmannans,
CD206 can induce NF-kB activation and the production of IL-12,
GM-CSF, IL-8, IL-1b, and IL-6. CD206 also appears to be
responsible for the formation of a novel DC phagocytic structure
called the ‘‘fungipod’’ whichmay promote yeast phagocytosis by
DC and play an important role in DC-fungi interactions (Neumann
and Jacobson, 2010). The role of CD206 in promoting fungal
antigen uptake, processing, and presentation by DC remains
poorly understood. However, due to the wide expression of442 Cell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc.CD206 on DC subsets, strategies to target vaccine antigen to
CD206 could result in broad DC mobilization and potentially
robust vaccine immunity.
NLR
Recently, a NOD-like receptor family member was found to play
a role in the antifungal immunity. Exposure of monocytes to
C. albicans germ tubes or A. fumigatus hyphae activated the
NLRP3 inflammasome in a Syk-dependent fashion (Hise et al.,
2009; Saı¨d-Sadier et al., 2010). NLRP3 is activated by a wide
range of pathogen- and host-associated stimuli, and it is unclear
if NLRP3 senses stimuli directly or indirectly. b-glucan also acti-
vates the NLRP3 inflammasome in DC, although this activation is
dispensable for antigen specific Th1 and Th17 polarization
(Kumar et al., 2009). Fungal structures recognized by NLRP3
may include surface carbohydrates, fungal DNA, or a fungal-
induced host factor signifying tissue damage such as ATP.
NLRP3 agonists such as aluminum hydroxide have been in use
as vaccine adjuvants for decades; thus discerning the mecha-
nism of fungal-induced NLPR3 activation could enhance future
vaccine designs against fungi and other pathogens.
Fungal Vaccine Strategies Targeting DC
Only a single clinical trial evaluating efficacy of a fungal vaccine
has been completed in humans (Pappagianis, 1993). A new
interest in fungal vaccine development has accompanied the
growing knowledge illuminating the critical determinants of
host defense against fungal pathogens.More importantly, recent
work suggests that it may be possible to create an antifungal
vaccine that grants protection against multiple fungal pathogens
(Wu¨thrich et al., 2011; Stuehler et al., 2011; Cassone and
Rappuoli, 2010). At the core of host resistance to fungi, is the
induction of strong cellular immunity via appropriate activation
of DC. Antiviral and antitumor vaccine strategies have leveraged
the central role of DC in driving CTL responses by first priming
autologous monocyte-derived DC with the desired antigen
ex vivo before readministering the loaded DC to the host. In
animal models, DC primed with fungi ex vivo promote antifungal
immunity in naive mice. Similarly, DC transfected with fungal
RNA ex vivo express fungal proteins on their surface and
promote the development of protective T cell responses (Bozza
et al., 2004). These procedures are time-consuming and expen-
sive, and for those reasons they are unlikely to bewidely adopted
in clinical medicine. However, recent technological advances in
antigen delivery, combined with a greater understanding of DC
biology, should allow for effective targeting and loading of DC
with immunogenic antigen in vivo.
Because of the dense network of DC in the skin, the lung, and
the intestine, vaccine delivery systems that target these DC
networks may be more potent (Figure 3). Indeed, when
comparing influenza vaccine injection routes, intradermal injec-
tion was more than twice as potent at eliciting antibodies than
subcutaneous administration in individuals between 18 and
60 years of age (Belshe et al., 2004). A current Phase I clinical
trial expected to be completed in early 2012 is evaluating the
safety of intravaginal application of a virosome-based recombi-
nant Sap2 therapeutic vaccine against recurrent vulvovaginal
candidiasis (VVC) (NCT01067131). Preclinical trials in mice
demonstrated rapid clearance of Candida and protection from
reoccurrence in a murine VVC model following intravaginal
Figure 3. DC-Based Strategies for Developing Antifungal Vaccines
DC subsets may be targeted by varying the route of administration: aerosols target lung DC subsets; intradermal injection targets skin DC. DC can be loaded
directly ex vivo before transfer into the host. Recombinant yeast contain ligands recognized by DC and allow for efficient DC uptake of antigen expressing
organisms. bglucan particles robustly activate DC via dectin-1. Virosomes also contain DC-targeting ligands and viral PRR ligands that activate DC. Nano-
particles represent a complete engineered solution that incorporates PRR ligands, DC-targeting ligands, and vaccine antigens. Following DC targeting, mature
DC present antigen and activate naive T cells.
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vaccination at these DC-rich sites may not represent a universal
approach to vaccination against fungi. For example, a live atten-
uated strain of B. dermatitidis engendered full protection when
administered subcutaneously, but not when administered intra-
nasally against a lethal pulmonary challenge in mice (Wu¨thrich
et al., 2000, 2012). Correspondingly, CCR2/ mice lacking
monocyte-derived inflammatory DC had impaired clearance of
A. fumigatus from the lung but not the spleen, demonstrating
an organ-specific role for this DC subset (Hohl et al., 2009).
The tissue microenvironment also modulates the function of
DC subsets and influences the ability of DC to prime effective
T cell responses. DC subsets in the spleen are able to drive
Th17 differentiation in the absence of IL-6, whereas DC from
the skin and the gut require IL-6 to drive Th17 polarization (Hu
et al., 2011). This suggests that the effect of local cytokine gener-
ation will need to be factored into fungal vaccine design when
considering a route of vaccination. Thus, the DC subtypes and
the tissue microenvironment at the vaccination site may critically
modulate vaccine responses to fungal antigens.
A more direct method to target DC is to covalently attach
antigen to DC-specific ligands. Fungal pathogens contain
substantially mannosylated proteins which are effectively endo-
cytosed by DC via CLR. In fact, mannosylation of the model
antigen OVA greatly enhanced its immunogenicity at least in
part by increasing its uptake by DC via CLR family members
CD206 and DC-SIGN (CD209) (Lam et al., 2007). Other fungal
carbohydrates also effectively target antigen to DC. Forexample, antigen-loaded b-glucan particles are actively taken
up by DC in a dectin-1 dependent manner. OVA-laden b-glucan
particle-exposed DC were more potent at inducing proliferation
of OVA-specific CD4+ and CD8+ T cells in vitro compared with
soluble OVA (Huang et al., 2010). Furthermore, subcutaneous
administration of OVA-laden b-glucan particles induced higher
OVA-specific T cell polarization toward a Th1 and Th17 pheno-
type than alum-adsorbed OVA and induced the secretion of
OVA-specific Th1-associated IgG2c antibodies. Incredibly, fungi
themselves are now being exploited to take advantage of direct
targeting and robust activation of DC via the b-glucan/dectin-1
interaction. In whole recombinant yeast immunization, antigen-
expressing S. cerevisiae yeast (which display b-glucan on their
surface) are administered with the goal of eliciting antigen-
specific host CD4+ and CD8+ T cell responses (Stubbs et al.,
2001). Completed Phase I trials indicate that S. cerevisiae-based
therapies are safe and well tolerated in humans, and Phase II
trials are currently ongoing (NCT00124215).
A complementary approach to whole recombinant yeast
immunization involves the use of nanoparticles in targeting
antigen to DC. Nanoparticles are internalized preferentially by
DC due to their submicron size and can be more specifically
targeted to DC through the addition of DC receptor (such as
Dec 205)-targeting antibodies or DC receptor ligands to their
surface. Nanoparticle-mediated targeting of DC enables the
bundling of defined antigen or antigens with an adjuvant and
a DC receptor-targeting molecule allowing for precise delivery
to DC. The elegance of this approach was recentlyCell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc. 443
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particle containing TLR3, TLR7, and TLR8 ligands and OVA
antigen (Tacken et al., 2011). This nanoparticle was designed
to target DEC205+ DC and to simultaneously deliver the antigen
and TLR ligand adjuvant. Targeting of the particles to DC
enhanced their immunogenicity, encapsulating the antigen
(OVA) increased the potency of the antigen, and codelivering
TLR ligands blocked the development of tolerance and reduced
overall toxicity. In total, the study suggests that nanoparticles
can deliver vaccine antigen to DC effectively, and that when
antigen and adjuvant are delivered together, strong immune
responses with limited toxicity can be induced. In a limited
way, the targeting nanoparticle loadedwith antigen and adjuvant
begins to resemble the microbial vaccine target itself.
Since the surfaces of fungi are covered in polysaccharide,
carbohydrate, or glycoconjugate antigens, they are attractive
targets for antifungal vaccine development. Vaccine strategies
based on both the glucuronoxylomannan component of the
cryptococcal polysaccharide capsule and b-1,3-glucan that is
expressed by a broad range of fungi have demonstrated the
ability to promote antibody-mediated protection against fungal
challenge. However, immunogenicity of glycoconjugates is
unpredictable, and the carbohydrate moiety is thought unable
to be recognized by T cells directly. Novel findings using
a defined glycoconjugate suggest that it is possible to design
vaccines where T cells recognize the carbohydrate directly
and that such glycoconjugates greatly enhance immunogenicity
(Avci et al., 2011). It is tantalizing to speculate that fungal
carbohydrates displayed by MHC II could be recognized by
T cells in the same way. Immunization with glycosylated
peptides was able to generate carbohydrate-specific CTL
responses (Abdel-Motal et al., 1996), suggesting that appropri-
ately designed glycoconjugates may be processed and cross-
presented to CD8+ T cells. As knowledge of cross-presentation
by DC increases, it may be possible to generate fungal carbo-
hydrate specific CTL responses against fungal pathogens. This
may be advantageous in immune-deficient patients lacking
CD4+ T cells, where CD8 T cells compensate and mediate
lasting vaccine-induced resistance to pathogenic fungi (Nan-
jappa et al., 2012).Conclusions
In this review, we have highlighted the role of diverse DC subsets
in antifungal immunity and discussed potential strategies to
target DC in the generation of novel antifungal vaccines.
Vaccines may be targeted to DC via interactions with surface
receptors or via other routes of administration and activate DC
through PRR. New vaccine construction technologies are
expanding the available pool of fungal antigens that induce
cell-mediated immunity to include carbohydrates and reduce
toxicity. Continuing to unearth the central role of DC in antifungal
immunity will suggest new avenues for the development of effec-
tive antifungal vaccines.ACKNOWLEDGMENTS
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